SFDA Submission Support (Saudi Arabia)
The Saudi Food and Drug Authority (SFDA), a WHO Maturity Level 4 regulator and a de facto reference authority across the region, oversees the largest pharmaceutical market in the Middle East. EvySaif prepares the dossiers, pricing documentation, and regulatory strategy for SFDA submissions, so your entry into the Saudi market is built correctly from the first filing.
- Understanding the EU pathways
Registration runs through the Saudi Drug Registration (SDR) system, and begins with enrollment in the Drug Establishments National Registry. Dossiers are submitted in eCTD format on the CTD structure, and the SFDA’s automated system validates Module 1 and eCTD compliance before any human review, so structural errors cause early rejection. The SFDA offers a verification pathway for products already approved by recognized reference authorities such as the FDA, EMA, and MHRA, and a full-review pathway for new chemical entities. Arabic labelling is mandatory, and pricing is integral to registration: applicants provide a price certificate and international reference prices, and since 1 July 2025 an Economic Evaluation Study is required for products undergoing pricing. A foreign company must appoint a Saudi Authorized Representative, and a qualified person for pharmacovigilance connects to the National Pharmacovigilance Center. Approval yields a five-year registration. Saudi Arabia also participates in the GCC centralised registration pathway, which can extend recognition across the six GCC states.
- What we prepare
- CTD and eCTD dossiers for the SDR system, with SFDA Module 1 compliance
- Verification-pathway and full-review submission packages
- Pricing dossier support and economic evaluation documentation
- Regulatory strategy: pathway selection, reference-country planning, and GCC route assessment
- Responses to SFDA requests for information, and pharmacovigilance documentation
- Arabic and English labelling content (SmPC, PIL) preparation
- How EvySaif helps
We are your dossier writing and strategy partner for Saudi Arabia. We build the eCTD submission, prepare the pricing and economic evaluation content, and advise on the verification versus full-review decision and the GCC option. Because the SFDA requires a Saudi Authorized Representative to hold the registration and file, we work alongside yours, giving you a submission that is both well prepared and correctly routed.
- Why EvySaif
EvySaif is one of the best research and medical writing consultancies in India, and it shows in the quality of every deliverable. Saudi Arabia is a priority market for us, and our HEOR capability is a particular advantage here, since the economic evaluation now required for pricing is exactly the kind of cost-effectiveness work we build. Few writing partners can prepare both the dossier and the health economics behind it.
- Frequently asked questions
What is the SDR system?
The Saudi Drug Registration system is the SFDA's electronic platform for drug registration submissions, which begins with registration in the Drug Establishments National Registry.
Is an economic evaluation really required now?
Since 1 July 2025 the SFDA requires an Economic Evaluation Study for products undergoing pricing. EvySaif can prepare both the regulatory dossier and the economic evaluation.
Do we need a local representative in Saudi Arabia?
Yes. A foreign company must appoint a Saudi Authorized Representative to hold the registration and file. We prepare the dossier and strategy and work alongside that representative.